Encellin, Inc., a clinical-stage biotechnology company developing Encapsulated Cell Replacement Therapy (ENCRT), today announced a partnership with Breakthrough T1D, the leading global Type 1 Diabetes ...

Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced updated long-term data from its Phase 2 BESTOW clinical program evaluating tegoprubart in patients undergoing kidney ...

T-cell lymphomas represent a heterogeneous and often aggressive group of hematologic malignancies for which the optimal consolidation strategy, autologous or allogeneic hematopoietic stem cell ...

While heart transplantation (HT) is the optimal therapy for end-stage heart failure patients, longevity of HT recipients ...

Researchers have successfully conducted the first clinical trial using activated regulatory T cells (ATregs, ...

Islet replacement provides a safe and effective therapy for type 1 diabetes, without the drawbacks inherent to insulin ...

Twenty years have passed since Professor Shinya Yamanaka announced iPS cells in 2006. The year 2026 should be remembered as the year this technology left the laboratory and became 'priced medicine.' ...

A seven-year-old boy has become one of the youngest patients in the UK to undergo a rare and complex pancreas surgery. Charlie Skidmore, from Oxfordshire, received the pioneering treatment at Oxford ...

Given the right conditions, certain types of cells are able to self-assemble into new lifeforms after the organism they were ...

A grant from Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization, to Brown ...

Seven years ago, Johns Hopkins researchers and their collaborators announced they had found the X cell, a novel immune cell ...

Long-term research funding support from the NIH might one day play a key role in reversing the progression of Type 1 diabetes ...